- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00464321
Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS
March 17, 2014 updated by: Genzyme, a Sanofi Company
A Phase I, Multicentre, Open-label, Dose-escalating Study of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
This study will investigate whether GC1008, an antibody which neutralizes TGF-beta, is safe in treating patients with the disease called focal segmental glomerulosclerosis (FSGS).
The highest dose without excessive side effects will be investigated.
Tests will determine how long GC1008 is in the body and how it is excreted.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Patients in each cohort will receive a single dose of GC1008 infusion at 1, 2, 4 or 0.3 mg/kg body weight.
The higher dose cohort will not start until the first 28 days safety data for the lower dose cohort have been reviewed by the independent Data Monitoring Committee (DMC).
Cohort C and D will run concurrently with patients randomised to receive either a 4 or 0.3 mg/kg body weight dose, respectively.
After receiving the infusion of GC1008 on Day 0, patients will be monitored for the 24 hours following the infusion.
Patients will return periodically over the following 112 days for safety evaluations and clinical outcome assessments.
Blood samples will be collected to evaluate the pharmacokinetics of single dose administration of GC1008 as well as for evaluation of markers of clinical efficacy
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany
-
Duesseldorf, Germany
-
Solingen, Germany
-
-
-
-
-
Bergamo, Italy
-
-
-
-
-
Cambridge, United Kingdom
-
-
-
-
California
-
San Francisco, California, United States
-
-
Minnesota
-
Rochester, Minnesota, United States
-
-
New York
-
New Hyde Park, New York, United States, 11042-1433
-
-
North Carolina
-
Chapel Hill, North Carolina, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- GFR≥25ml/min/1.73m2 calculated by the MDRD equation
- Urinary total protein: creatinine ratios >200mg/mmol derived from the average of 2 first morning voids taken during screening period
- Biopsy confirmed as idiopathic FSGS by a central reviewer
- Treatment resistance. NOTE:Patients to have received minimum 6 week course of steroids or immunosuppressant
- If receiving treatment with an ACEi and/or ARB dose to be stable for a minimum of 4 weeks prior to randomization
- Influenza vaccine (according to season)
- Negative screening per American Cancer Society (ACS) 2003 guidelines, as appropriate to patient demographics and clinical status
Exclusion Criteria:
- Secondary FSGS
- steroid resistant patients who are unable to reduce their steroid dose to <10mg/day of prednisolone or equivalent 4 weeks prior to study dosing day
- Positive serology for serious infections (including but not limited to infection with Hep B or C, HIV)
- Concomitant illnesses:Diabetes Type I; Cardiac or Hepatic disease, HIV; Cancer, precancerous state (eg familial adenomatous polyposis; Any condition requiring treatment with other immunosuppressant drugs within 4 weeks prior to dosing day or during the course of the study
- Pre-existing oral-pharyngeal disease (dental carries and other minor dental disease are acceptable)
- Haemoglobin level of <9.0g/dL prior to dosing
- Treatment with coumadin, anti-vitamin K analogues or low molecular weight heparins. Patients must have stopped treatment a minimum of four weeks prior to receiving study medication.
- Patients requiring ongoing treatment with non-steroidal anti-inflammatory drugs (NSAIDs). Patients must have stopped treatment a minimum of four weeks prior to receiving study medication.
- Patients who have had surgery/fracture within 3 months prior to dosing day
- History of cancer unresolved within 5 years prior to screening or a known precancerous state; or any form of skin cancer either current or past history
- Women who are pregnant, lactating or who plan to become pregnant within 4 months of infusion
- Women of childbearing potential unless taking medically acceptable contraceptive
- Men with female partners of childbearing potential unless they are taking medically acceptable contraceptive precautions
- Use of any investigation drug administered as part of a clinical trial within 4 weeks prior to commencing screening
- Other clinically significant, uncontrolled medical condition that in the investigator's opinion may interfere with the assessment or follow-up
- Active ethanol or drug abuse, excluding tobacco use
- Electrocardiogram (ECG) abnormalities considered to be clinically significant at screening
- Unable to comply with the requirements of the study
- Active thrombophlebitis, thromboembolism, hypercoagulability states, bleeding, or use of anticoagulation therapy (including anti-platelet agents). Patients with a history of deep venous thrombosis may participate if successfully treated, completely resolved, and no treatment has been given for >4 months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A
Dose Group
|
1 mg/kg, IV infusion on Day 0 and monitored over 24 hours.
Post infusion for safety up to 112 days.
2 mg/kg, IV infusion on Day 0 and monitored over 24 hours.
Post infusion for safety up to 112 days.
4 mg/kg, IV infusion on Day 0 and monitored over 24 hours.
Post infusion for safety up to 112 days.
0.3 mg/kg, IV infusion on Day 0 and monitored over 24 hours.
Post infusion for safety up to 112 days.
|
Experimental: Cohort B
Dose Group
|
1 mg/kg, IV infusion on Day 0 and monitored over 24 hours.
Post infusion for safety up to 112 days.
2 mg/kg, IV infusion on Day 0 and monitored over 24 hours.
Post infusion for safety up to 112 days.
4 mg/kg, IV infusion on Day 0 and monitored over 24 hours.
Post infusion for safety up to 112 days.
0.3 mg/kg, IV infusion on Day 0 and monitored over 24 hours.
Post infusion for safety up to 112 days.
|
Experimental: Cohort C
Dose Group
|
1 mg/kg, IV infusion on Day 0 and monitored over 24 hours.
Post infusion for safety up to 112 days.
2 mg/kg, IV infusion on Day 0 and monitored over 24 hours.
Post infusion for safety up to 112 days.
4 mg/kg, IV infusion on Day 0 and monitored over 24 hours.
Post infusion for safety up to 112 days.
0.3 mg/kg, IV infusion on Day 0 and monitored over 24 hours.
Post infusion for safety up to 112 days.
|
Experimental: Cohort D
Dose Group
|
1 mg/kg, IV infusion on Day 0 and monitored over 24 hours.
Post infusion for safety up to 112 days.
2 mg/kg, IV infusion on Day 0 and monitored over 24 hours.
Post infusion for safety up to 112 days.
4 mg/kg, IV infusion on Day 0 and monitored over 24 hours.
Post infusion for safety up to 112 days.
0.3 mg/kg, IV infusion on Day 0 and monitored over 24 hours.
Post infusion for safety up to 112 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine Safety and tolerability of single dose infusions of GC1008 in patients with treatment resistant idiopathic FSGS and nephrotic range proteinuria
Time Frame: up to 2 years
|
up to 2 years
|
Pharmacokinetics of GC1008 following a single dose infusion
Time Frame: up to 2 years
|
up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To investigate Effect of single dose infusions of GC1008 on biomarkers of clinical efficacy.
Time Frame: up to 2 years
|
up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2007
Primary Completion (Actual)
January 1, 2010
Study Completion (Actual)
February 1, 2010
Study Registration Dates
First Submitted
April 20, 2007
First Submitted That Met QC Criteria
April 20, 2007
First Posted (Estimate)
April 23, 2007
Study Record Updates
Last Update Posted (Estimate)
March 19, 2014
Last Update Submitted That Met QC Criteria
March 17, 2014
Last Verified
March 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GC1008FSGS00505
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Focal Segmental Glomerulosclerosis
-
Genzyme, a Sanofi CompanyCompletedPrimary Focal Segmental GlomerulosclerosisUnited States, Brazil, Germany, Italy, Spain
-
Nanjing University School of MedicineWithdrawnFocal GlomerulosclerosisChina
-
National Institute of Diabetes and Digestive and...The Cleveland ClinicCompleted
-
Complexa, Inc.Medpace, Inc.; MicroConstants; Kidney Research Network, formerly NephCure Accelerating... and other collaboratorsCompletedPrimary Focal Segmental GlomerulosclerosisUnited States
-
National Institute of Diabetes and Digestive and...Genentech, Inc.; Indiana UniversityCompletedFocal Segmental Glomerulosclerosis (FSGS)United States
-
Mayo ClinicUniversity Health Network, Toronto; National Institute of Diabetes and Digestive... and other collaboratorsCompletedPrimary Focal Segmental GlomerulosclerosisCanada, United States
-
National Institute of Diabetes and Digestive and...Completed
-
Mallinckrodt ARD LLCCompletedIdiopathic Focal Segmental GlomerulosclerosisUnited States, Argentina, Turkey, Peru, Australia, Chile, Mexico
-
NYU Langone HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaboratorsCompletedFocal Segmental GlomerulosclerosisUnited States, Canada
-
Northwell HealthTerminatedFocal Segmental Glomerulosclerosis
Clinical Trials on GC1008
-
Boston UniversityCompleted
-
University Medical Center GroningenGenzyme, a Sanofi CompanyCompleted
-
Weill Medical College of Cornell UniversityUniversity of California, Los AngelesCompleted
-
Abramson Cancer Center of the University of PennsylvaniaCompletedPleural Malignant MesotheliomaUnited States
-
Genzyme, a Sanofi CompanyCompletedIdiopathic Pulmonary FibrosisUnited States, Belgium
-
Maximilian DiehnVarian Medical SystemsCompletedStage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
Genzyme, a Sanofi CompanyCompletedMelanoma | Carcinoma, Renal CellUnited States
-
John MascarenhasTerminatedPrimary Myelofibrosis | Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Post-essential Thrombocythemia Related MyelofibrosisUnited States